Comparative Pharmacology
Head-to-head clinical analysis: ENDEP versus NORTRIPTYLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDEP versus NORTRIPTYLINE HYDROCHLORIDE.
ENDEP vs NORTRIPTYLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake in the central nervous system.
Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminic, and alpha-adrenergic blocking properties.
Initial 75 mg/day orally in divided doses, increased gradually to 150-200 mg/day; maintenance 50-150 mg/day as single dose at bedtime or in divided doses.
25 mg orally three times daily or 75 mg orally once daily at bedtime; initial dose 25 mg at bedtime, titrate up to 75-150 mg/day.
None Documented
None Documented
Terminal elimination half-life: 15-40 hours (mean ~24 h); clinical context: steady-state achieved in 5-7 days; prolonged in elderly and CYP2D6 poor metabolizers.
Terminal elimination half-life 18-56 hours (mean 28 hours); steady-state reached in 5-7 days.
Renal: 70-80% as metabolites (including glucuronides, unchanged drug <5%); Biliary/Fecal: 20-30%.
Primarily renal (70% as metabolites, <5% unchanged) and fecal (30% via biliary elimination).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant